Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ZG 005

Next Previous
X
Search
Drug Profile

ZG 005

Alternative Names: ZG-005

Latest Information Update: 21 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gensun Biopharma
  • Developer Suzhou Zelgen Biopharmaceuticals
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants; TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cervical cancer; Neuroendocrine carcinoma; Solid tumours

Most Recent Events

  • 16 Aug 2024 Suzhou Zelgen Biopharmaceuticals plans a phase II trial for Liver cancer (Late-stage disease, combination therapy, First-line therapy) in China (IV, Injection) in September 2024 (NCT06558227)
  • 31 May 2024 Efficacy and adverse events data from a phase I/II trial in Solid tumors presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 30 May 2024 Phase-I/II clinical trials in Neuroendocrine carcinoma (Combination therapy, Late-stage disease, Recurrent, Metastatic disease) in China (IV) (NCT06372626)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top